ENXTAM:PHARMBiotechs
Pharming Group (ENXTAM:PHARM) Stock Faces Revenue Reset Despite Positive EPS
Pharming Group went into this earnings day with the stock under pressure, down roughly 39% over the past three months and closing at €0.8782. Yet the headline from the numbers is not collapse; it is a profitability reset that clashes with the gloomy share price trend. Q2 total revenue came in at US$90.2m with net income of US$1.6m, and earnings per share moved back into positive territory. The market is still trading Pharming Group like a problem story, while the income statement reads more...